MD Anderson Events

Symphogen will present its pipeline of oncology therapeutics from 8:00 - 9:00 a.m., followed by 30 minutes of Q&A.  Come meet the company, hear about their programs, and explore the possibility of collaboration.

 

"Symphogen is developing recombinant antibody mixtures, a new class of antibody therapeutics for the treatment or prophylaxis of serious human diseases.  By employing its pioneering antibody discovery and manufacturing technologies, Symphogen generates recombinant antibody compositions that capture the diversity and effectiveness of the natural immune system. Symphogen’s pipeline of product candidates and development programs address large and growing markets, such as the replacement of plasma-derived immunoglobulins, oncology, and a broad range of infectious diseases.  Symphogen is also developing therapeutic alternatives to monoclonal antibodies."